Cell surface proteins can play important roles in cancer pathogenesis. Comprehensive understanding of the surface protein expression patterns of tumor cells and, consequently, the pathogenesis of tumor cells depends on molecular probes against these proteins. To be used effectively for tumor diagnosis, classification and therapy, such probes would be capable of specific binding to targeted tumor cells. Molecular aptamers, designer DNA-RNA probes, can address this challenge by recognizing proteins, peptides and other small molecules with high affinity and specificity. Through a process known as cell-based SELEX, we used live acute myeloid leukemia (AML) cells to select a group of DNA aptamers, which can recognize AML cells with dissociation constants (Kd's) in the nanomolar range. Interestingly, one aptamer (KH1C12) compared with two control cell lines (K562 and NB4) showed significant selectivity to the target AML cell line (HL60) and could recognize the target cells within a complex mixture of normal bone marrow aspirates. The other two aptamers KK1B10 and KK1D04 recognize targets associated with monocytic differentiation. Our studies show that the selected aptamers can be used as a molecular tool for further understanding surface protein expression patterns on tumor cells and thus providing a foundation for effective molecular analysis of leukemia and its subcategories.
Introduction
Acute leukemia has been traditionally classified according to the French-American-British system, which is based on morphology and cytochemistry studies. In 2001, the World Health Organization classification system of acute leukemia was introduced. Therefore, a new basis for diagnosing both adult and pediatric acute leukemia has been established. This is based on a combination of cytological examination, immunophenotypic analysis by flow cytometry and cytogenetic karyotyping, or molecular analysis of genetic mutations known to carry good or poor risk for patients. 1 Because of the relatively simple technical requirements and short turnaround time, immunophenotyping and monitoring residual diseases in clinical practice by flow cytometry has been the method of choice. However, the available monoclonal antibodies are only used to classify tumors by tissue origin or lineage, not to identify the molecular events underlying the neoplastic process or the information required to aggressively pursue prognosis and clinical management. 2 This picture changes significantly when we consider cell surface proteins, which can play important roles in cell proliferation and differentiation in response to extracellular stimulatory and inhibitory signals. 2 Specifically, the differences in surface protein expression among various types of tumor cells can potentially be used to diagnose and detect tumor cells and predict their behavior. Such differentiation in protein expression also gives the clues required to predict effective therapeutic regimens, perform targeted therapy, as well as determine longterm outcomes. 1 However, to define the molecular basis of a disease process, we must be able to generate the molecular signature of an individual disease. Therefore, by developing probes that can recognize surface proteins, it will open opportunities that can ultimately aid in profiling the surface protein changes that are related to neoplasia or diseases, and classify tumors according to their molecular characteristics instead of tissue origin or cell lineages.
In our earlier studies, 3, 4 we used a cell-based aptamer selection strategy known as cell-based SELEX to develop aptamers, which distinguish target cells Children's Cancer Research Foundation, (CCRF)-CEM, human precursor T-cell acute lymphoblastic leukemia) from the control B-cell tumor (Ramos, human Burkitt's lymphoma) and vice versa. Having been derived from the normal B and T lymphocytes, the tumor cells of B-or T-cell lineage have distinctive surface proteins, which is the reason we chose them to implement our aptamer selection strategy. We found that a panel of selected aptamer probes could recognize CEM T-cell acute lymphoblastic leukemia or Ramos cells mixed with normal human bone marrow cells and also real clinical specimen, showing the potential clinical application of leukemia cell detection and characterization. However, we still needed to validate the potential of this strategy in identifying specific molecular markers in closely related tumor cells. Consequently, in this paper, we report the applicability of this procedure in two closely related acute leukemia cell lines, HL60 and NB4.
HL60 and NB4 cells are morphologically similar and can undergo in vitro granulocytic differentiation when treated with retinoic acid, 5 a characteristic feature of Acute Promyelocytic Leukemia (APL). NB4, a model APL cell line, has the t(15; 17) translocation involving the retinoic acid receptor alphagene. The resultant fusion proteins created by the specific translocation disrupt the function of retinoic acid receptor-, which blocks the normal maturation of granulocytes, thus leading to the accumulation of abnormal promyelocytes. Treatment with all-trans retinoic acid (ATRA), a derivative of vitamin A, causes differentiation of the immature leukemic promyelocytes into mature granulocytes. 6 HL60 cells can also be induced to differentiate by ATRA, even though HL60 cells lack this chromosomal translocation. The underlying mechanism for such induced HL60 cell differentiation remains unclear. Both NB4 and HL60 cell line can be induced to differentiate toward monocytic and granulocytic pathways depending on the chemical inducer. 1 By using the model system, we examine whether it is possible to select aptamers capable of detecting the difference in the surface protein expression between these closely related cell lines.
Materials and methods
Cell lines and cell culture HL60, NB4 (t (15; 17) (q22; q12)), K562 (t (9; 21) (q34; q11)), CEM, Ramos, Jurkat cell lines, Kasumi-1 (t(8; 21) (q22; q22)), Monomac-6 (t(9; 11) (p22; q23)), HEL and MV4-11 (t(4; 11) (q21; q23)) were used for the studies. All cells were maintained in culture with Roswell Park Memorial Institute (RPMI)-1640 (American Type Cell Culture, Manassas, VA, USA) culture media, supplemented with 20% heat-inactivated fetal bovine serum (FBS) (Kasumi-1 and MV4-11) and the rest with 10% FBS and 100 U/ml penicillin-streptomycin (Mediatech Inc., Manassas, VA, USA). They were incubated at 37 1C in a 5% CO 2 atmosphere. The leftover human bone marrow samples were obtained from the Hematopathology Laboratory, Department of Pathology, University of Florida/Shands Hospital.
DNA primers and library
The DNA library used for cell-based aptamer selection consisted of a pool of oligonucleotides made up of a continuous stretch of 45 randomized nucleotides flanked on both ends by PCR primer sequences. The 5 0 end is labeled by fluorescein isothiocyanate (FITC) (5 0 -FITC-ATCCAG AGTGACGCAGCAN45TGGACACGG TGGCTTAGT-3 0 ). The forward primer was labeled at the 5 0 end with FITC (5 0 -FITC-ATCCAGAGTGACGCAGCA-3 0 ) and the reverse primer with biotin at the 5 0 end (5 0 -Biotin-ACT-AAG CCACCGTGTCCA-3 0 ). All sequences were synthesized by standard phosphoramidite chemistry using a 3400 DNA synthesizer (Applied Biosystems Inc., Foster City, CA, USA) and purified by reverse phase HPLC (Varian Analytical Instruments, Walnut Creek, CA, USA). During selection, eluted sequences were amplified by PCR and the FITC-labeled sequences were separated from the biotinylated complementary strand by denaturation (200 mM NaOH) and streptavidin-biotin interactions. All PCR mixtures contained 50 mM KCl, 10 mM TrisHCl (pH 8.3), 1.5 mM magnesium chloride (MgCl 2 ), dNTPs (each at 2.5 mM), 0.5 mM each primer and Hot start Taq DNA polymerase (5 U/ml). Amplifications were carried out in a Biorad 1 Cycler at 95 1C for 30 s, 56.3 1C for 30 s and 72 1C for 30 s, followed by the final extension for 3 min at 72 1C. The FITClabeled sequences were used to continue and monitor progress of selection by flow cytometry.
Cell-based selection
In this study, HL60 was used as target (positive cell line) and NB4 for counter selection (negative cell line). In total, 20 nmol of DNA library was dissolved in 500 ml of binding buffer (4.5 g/l glucose, 5 mM MgCl 2 , 0.1 mg/ml tRNA and 1 mg/ml BSA, all dissolved in Dulbecco's phosphate-buffered saline with MgCl 2 and calcium chloride). The DNA pool was denatured at 95 1C for 5 min and quickly cooled on ice for 10 min. The detailed SELEX procedure is outlined in earlier studies. 3 Briefly, 5 Â 10 6 HL60 cells were washed twice with washing buffer (4.5 g/l glucose, 5 mM MgCl 2, dissolved in Dulbecco's phosphatebuffered saline with 0.1 g/l MgCl 2 and 0.133 g/l calcium chloride) and centrifuged at 940 r.p.m. for 5 min at 4 1C. The cells were incubated with the DNA pool in binding buffer on ice in an orbital shaker for 45 min. After incubation, the cells were washed three times to remove unbound DNA sequences. The bound DNA sequences were eluted with 500 ml binding buffer by heating at 95 1C for 10 min and centrifugation. The supernatant containing the DNA sequences was incubated with 2 Â 10 7 NB4 cells to perform a subtraction. The unbound sequences were amplified by PCR using FITC-and biotinlabeled primers. The selected sense ssDNA was separated from the biotinylated antisense ssDNA by alkaline denaturation and affinity purification with streptavidin-coated Sepharose beads (GE Healthcare Bio-Sciences Corp., Piscataway, NJ, USA). The entire selection process was repeated according to the extent of enrichment. To acquire aptamers with high affinity and specificity, the washing strength was enhanced gradually by extending wash time (2-5 min), as well as increasing the volume of washing buffer (3-5 ml) and the number of washes (3-5 times). Additionally, an increased amount of FBS (10-20%) was added to the incubation mixture, while the number of cells was reduced from five million to one million. The enrichment of specific sequences was monitored using flow cytometry. By 16 rounds of selection, there was significant enrichment of DNA sequences to enable selective recognition of the target cells rather than the negative cell line. The enriched pool was amplified by PCR using unlabeled primers and the PCR products cloned into Escherichia coli using TOPO TA cloning Kit for sequencing (Invitrogen, Carlsbad, CA, USA). The positive clones were sequenced by a high-throughput sequencing facility at the University of Florida.
Flow cytometry assays
Using flow cytometry to monitor aptamer binding to cultured cells. The enrichment of aptamer candidates during selection was determined by flow cytometry. The FITC-labeled ssDNA at a final concentration of 250 nM was incubated with 1 Â 10 6 target, or negative control cells, in 200ml binding buffer containing 20% FBS and placed on ice for 30 min. The cells were washed twice with binding buffer, and the pellets with the bound sequences were resuspended in 350 ml binding buffer. The fluorescence intensity was determined with a FACScan cytometer (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA) by counting 30 000 events. The FITC-labeled unselected ssDNA library was used as a negative control. To determine the cell specificity of the selected aptamers, cell lines including K562, Monomac-6, HEL, Kasumi-1, MV4-11, Jurkat, Ramos and CEM were used in binding assays by flow cytometry Determination of aptamer affinity. The screening of potential aptamers and the binding affinity of the successful aptamer candidates were performed using flow cytometry. To determine the binding affinity of the aptamers, target cells (1 Â 10 6 ) were incubated with varying concentrations of FITClabeled aptamer in a 200 ml volume of binding buffer containing 20% FBS. Cells were washed twice with binding buffer, resuspended in 350 ml buffer and analyzed by flow cytometer. The FITC-labeled unselected library was used as a negative control to determine nonspecific binding. All binding assays were in triplicate. The mean fluorescence intensity of the unselected library was subtracted from that of the aptamer with the target cells to determine the specific binding of the labeled aptamer. The equilibrium dissociation constant (Kd) of the aptamer-cell interaction was obtained by fitting the dependence of intensity of specific binding on the concentration of the aptamers to the equation Y ¼ B max X/(Kd þ X), using Sigma Plot (Jandel, San Rafael, CA, USA).
Competition assays. Cell-based selection may identify multiple aptamers for multiple targets, as well as multiple aptamers for a single target. Therefore, we tested the selected aptamers for competition against each other. We tested aptamers selected at the same time, as well as those known to bind to leukemia cell lines. 3 In competition assays, unlabeled competitive aptamer was incubated with HL60 cells in 10-fold excess concentration (2.5 mM), and then the labeled aptamer was added at a final concentration of 250 nM. The cells were washed and their fluorescence intensity was determined by flow cytometry.
Effect of temperature on the binding of KH1C12. As the selection of the aptamers was done on ice, all of the binding assays reported here were performed at a temperature of 4 1C.
We have observed that some of the aptamers selected at lower temperatures may not bind well at elevated temperatures, such as 37 1C, and that this may affect further studies using such aptamers in physiological conditions. We, therefore, performed binding assays at 37 1C to verify the stability of aptamer binding to its target. Three separate assays were performed. In set one, the aptamer was heated to 95 1C and cooled on ice immediately, whereas in sets two and three, it was cooled to room temperature and 37 1C, respectively. Aptamers were incubated with the target at 37 1C, and fluorescence intensity was determined by flow cytometry. Aptamers denatured at 95 1C, cooled immediately at 4 1C and incubated on ice were used as positive control.
Test-selected aptamers with cells in normal human bone marrow cells and acute leukemia cells. We tested the recognition pattern of the selected aptamers with the different types of cells in normal bone marrow aspirates. FITC-labeled aptamer, together with peridinin-chlorophyll-protein-labeled anti-CD45 antibody (PerCP-CD45, BD Biosciences, San Jose, CA, USA), were incubated with normal bone marrow aspirates. FITC-labeled unselected DNA library was used as a control. We next tested the feasibility of using an aptamer to identify its target when it is mixed with normal human bone marrow aspirates. Again, FITC-labeled aptamer was mixed with PerCP-labeled anti-CD45 and incubated with a mixture of normal bone marrow aspirates and HL60 or NB4 cells. These mixtures were assayed by flow cytometry. We also determined the interaction of the selected aptamers with real clinical patient samples. Different leukemia samples were tested, including acute myeloid leukemia (AML), APL, T-and B-cell acute lymphoblastic leukemia. FITC-labeled aptamers were mixed with PerCP-labeled anti-CD45 and/or R-phycoerythrin-labeled anti-CD117 antibody, (PE-anti-CD117, BD Biosciences).
Chemically Induced differentiation Assays. Differentiation agents, ATRA and butyric acid sodium salt were obtained from Sigma. ATRA was dissolved in ethanol and sodium butyrate in water at stock concentrations of 10 mM and 0.5 M, respectively. These were aliquoted and stored. Before induction of differentiation, HL60 and NB4 cells were quantified and assessed for viability by tryphan blue dye exclusion test on hemacytometer. Cells (viability over 95%) were seeded in RPMI-1640 at 100 000 cells/ml in total volume of 5 ml per each sample in petri dishes. Differentiation was induced at final concentrations of 1 mM ATRA (granulocytic pathway) and 0.5 mM sodium butyrate (monocytic pathway). The cells were incubated at 37 1C in a humidified atmosphere of 5% CO 2 . Control experiments were done with equal volumes of ethanol for ATRA experiments and water for sodium butyrate. All experiments were done in triplicate. The extent of differentiation was assessed between 1-5 days by nitroblue tetrazolium (NBT) reduction assay and the functional recognition of the aptamer probes also assessed by flow cytometry.
NBT reduction test. NBT reduction was performed using standard methodology, and the percentage of cells that contained intracellular black formazan deposits was determined. Briefly, treated and untreated cells at specific time points of inducer exposure were washed with phosphate-buffered saline and approximately 100 000 cells in 50 ml volume incubated with NBT solution at 37 1C for 30 min. Cytospin slide preparations were made and the smear allowed to dry. Cells were stained with Accustain Wright stain. Differential counts were performed under light microscope (Leica Microsystems Inc., Bannockburn, IL, USA) on minimum count of 200 cells. The percentage of cells containing intracellular formazan deposits was determined.
Binding studies of aptamers with differentiated cells by flow cytometry. The effect of differentiation of HL60 and NB4 cells on the binding pattern of KH1C12, KK1B10 and KK1D04 was determined. At the same time points of differentiation used for the NBT reduction test, portions of the cells were incubated with the aptamers at a final concentration of 250 nM for 30 min on ice. The cells were washed and assayed by flow cytometry. Unselected DNA library was used as a background fluorescence signal. The fluorescence intensity of the individual aptamers was compared with the control cells without differentiation.
Verification of aptamers binding to monocytic-differentiated cells. This assay was done with normal bone marrow cells. The cells were incubated with specific aptamers labeled with biotin at the 5 0 end and the fluorescence signal detected using phycoerythrin-labeled streptavidin. Each individual aptamer was incubated alongside with monocyte-specific monoclonal antibodies anti-CD14 labeled with allophycocyanin and FITC-labeled anti-CD64. After incubation and washing, the florescence signal was detected by flow cytometry.
Results

Selection and binding assays
Cell-based SELEX was effectively used for the selection, using HL60 as positive and NB4 as negative cell lines. A random ssDNA pool (approximately 10 14 ) was subjected to sequential binding and elution to enrich DNA sequences that can recognize surface markers of the target cells. Two myeloid cell lines, HL60 and NB4, were chosen as the model system to select DNA sequences for differential recognition. HL60 was used as the target cell line and NB4 for counter selection. The introduction of counter selection provides the opportunity to eliminate, as much as possible, common surface markers while enriching differential markers on the target cells. DNA pool collected after each round of selection was amplified by PCR. The enrichment of the DNA pool through successive selection was monitored by flow cytometry. The increased fluorescence intensity is an indication of the enrichment of cell-binding DNA sequences (Figure 1 ). With the increasing numbers of selection cycles, there was steady increase in the fluorescence intensity on the target cells, whereas there was no significant change of fluorescence intensity on the control cells. By the 16th round of selection, the fluorescence signals on the target cells significantly exceeded those on the control cells. This notwithstanding, the enrichment fluorescence intensity seemed not to be very large as is generally observed between target and control cells. We believe that this observation is due to the closeness of these two cell lines. In addition, the intensity of the fluorescence signal can be influenced by the coupling efficiency of the fluorophore.
The significantly enriched DNA pool was used for DNA cloning, and the positive clones were sequenced using a highthroughput sequencing facility at the Interdisciplinary Center for Biotechnology Research, University of Florida. The DNA sequences were grouped into families based on their sequence homology. Representative sequences from the different families were chosen to test their interactions with the target cells. Out of the initial 10 sequences tested, 8 showed significant binding to the target, HL60 ( Table 1) . We then determined the dissociation constant for some of the selected aptamers ( Figure 3) , and all were in the nanomolar range. As shown in Table 1 and Figure 2 , KH1C12 and KHG11 showed selective binding to the target, and they bound to target with very high affinity (Kd ¼ 5.4 ± 1.6 and 6.1±2.1 nM, respectively). In general, the nanomolar range dissociation constants of the selected aptamers compare well with that of antibodies.
We tested the influence of the other aptamers selected along with KH1C12, as well as those known to bind to leukemia cell lines, 3 on the binding of KH1C12 to its target. Ten-fold excess of the unlabeled competitor was first incubated with HL60 before cells were incubated with KH1C12 to ensure the competitive advantage. As shown in Supplementary Figure 1 , only KHG11 could block the binding of KH1C12. As a positive control to check the effectiveness of the assay, the unlabeled KH1C12 also blocked the binding of the FITC-labeled KH1C12 (Supplementary Figure 2k ). The observation that KHG11 influences the binding of KH1C12 suggests that these aptamers bind to the same target and/or to the same binding pocket though they have significant sequence diversity ( Table 1) . None of the other selected aptamers had any influence on the binding of KH1C12. This result further confirmed the binding specificity of selected aptamers.
As the KH1C12 aptamer showed better affinity than KHG11, and initial study suggesting that both seem to bind to the same molecule on target cell, KH1C12 was further characterized for its interaction with other cell lines, including myeloid and T-and B-cell leukemia lines. As shown in Table 2 , aptamer KH1C12 showed no recognition at all to T-and B-cell lines tested ( Supplementary Figure 2) . On the other hand, we observed a differential recognition pattern to myeloid cell lines. Aptamer KH1C12 did not have any interaction with the K562 (erythroid leukemia cell line with t(9; 22) translocation) or HEL (erythroleukemia) cell lines. However, some level of recognition was observed with Kasumi-1, t(8, 21) translocation (AML-M2), Monomac-6 (AML-M5) and MV4-11 (biphenotypic B myelomonocytic leukemia) ( Table 2 and Supplementary Figure 1) .
The stability of aptamer binding to target cells was also assessed at different temperatures. As aptamers were selected at 4 1C, a study was done to verify the suitability of using this aptamer at physiological temperature. The aptamer/ cell mixtures were incubated at 4 1C, room temperature and 37 1C. As shown in flow cytometry binding assays in Supplementary Figure 3 , there was no significant change in fluorescence intensities among the three different tempera-tures tested. This observation is important for further development of assays testing the uses of these aptamers for targeted therapy or for apoptotic and viability assays at physiological conditions.
Testing on normal human bone marrow aspirates and patients' leukemia samples using selected aptamers
Although there are significant differences between patients' leukemia cells in clinical samples and established leukemia cell lines, 7 considering this variability, we assessed the suitability of using the selected aptamers for molecular recognition of leukemia cells in clinical samples. These aptamers were used, along with characteristic monoclonal antibodies, as positive controls. As a first step, the FITC-labeled aptamer was incubated with normal bone marrow aspirates. KH1C12 showed no recognition with any subpopulation of the normal bone marrow aspirates (Figure 4a ). However, when the bone marrow aspirates were mixed with HL60 or NB4 cells, and incubated with the aptamer, KH1C12 could selectively recognize the target HL60 cells (Figure 4b) , but not the negative control NB4 cells (Figure 4c ). This property may be useful especially when real clinical specimen is involved. Generally, leukemia clinical specimen has diverse cell constituents and the importance of a probe to single out diseased cells cannot be overemphasized. The recognition of the selected aptamers with clinical samples was diversed. As shown in Table 3 , the selected aptamers showed between 20 and 40% recognition of the AML patients' samples tested. Interestingly, Sgc4 showed 70% recognition to AML samples but, however, showed broad recognition to 
Effect of differentiation on aptamer binding
Several studies have reported that NB4 and HL60 differentiation pathways are associated with ATRA and sodium butyrate induction. [8] [9] [10] [11] [12] We, therefore, used the NBT reduction test to assess and confirm that leukemic blasts differentiate into peroxidase-positive leukocytes (neutrophils and monocytes). Upon induction of ATRA, NB4 and HL60 cells differentiate along the granulocytic pathway, whereas sodium butyrate induces the monocytic pathway. Boyd and Metcalf 11 reported that sodium butyrate induced differentiation in virtually 100% of HL60 cells over a 4-day interval to cells with multiple phenotypic markers of monocytes. Treatment of HL60 and NB4 cells with 1 mM ATRA and 0.5 mM sodium butyrate was studied for up to 5 days. Continued exposure of the cells to these T-cell, ALL À Jurkat T-cell, ALL À Abbreviations: AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; CML, chronic myeloid leukemia; ALL, acute lymphoblastic leukemia. The fluorescence intensity of KH1C12 with HL60 cells was chosen as the maximum with an estimated 495% of cell binding (++++). The fluorescence intensities with other cell lines were, therefore, compared and accordingly assigned approximate binding intensity. A '-' indicates that the fluorescence intensity is similar to that of the unselected library. KH1C12 interaction with normal bone marrow cells (a) and its recognition with HL60 and NB4 cells, each in mixture with normal bone marrow aspirates. FITC-labeled KH1C12 and PerCP-labeled anti-CD45 antibody were incubated with HL60 (b) and NB4 cells (c) mixed with normal bone marrow aspirates (blue dots: lymphocytes, green dots: granulocytes and red dots: leukemic cells). The incubation mixtures were assayed by flow cytometry. KH1C12 could recognize HL60, but not NB4, in mixture with normal bone marrow cells. This is shown by the increase in fluorescence intensity in FL1-Height of the red dots (b), but not in (c).
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Table 3
Recognition of leukemia clinical samples by the selected aptamers (Figures 5a,  b, c and 6a, b, c) . Associated with these events, the selected aptamers showed various patterns of recognition to the differentiated cells. Generally, KH1C12 did not show any observable change in fluorescence intensity among the treated HL60 cells with ATRA and sodium butyrate (Figures 5e, f and 6e, f) and the controls (Figures 5d and 6d ), suggesting that there was no significant change in the expression level of target. On the other hand, KK1B10 and KK1D04 produced significant change in binding patterns with both cell lines. Both aptamers lost significant fluorescence signal (KK1D04 reduced to background) with ATRA-induced HL60 and NB4 cells (Figures 5h, k  and 6h, k) . In contrast, they showed an increase in fluorescence signal intensity when cells were induced to differentiate with sodium butyrate (Figures 5i, l and 6i, l) . These findings suggest that the targets recognized by KK1B10 and KK1D04 are upregulated when leukemic cells differentiate toward monocytic cells. The observation that the florescence signal intensity of KK1B10 and KK1D04 was increased with monocytic-differentiated HL60 and NB4 cells was further assessed with monocytic cells from bone marrow aspirate. The assay was done alongside with monocyte-specific antibodies CD14 and CD64. The aptamers KK1B10 and KH1C12 were used in this assay. Figure 7a shows the various cell types in bone marrow aspirate. The gated area, showing high-florescence signal for CD64 represents monocytes. The aptamers KH1C12 and KK1B10 response to these monocytes are represented in Figures 7b-e. KH1C12 shows some level of recognition in all stages of the monocytic population as shown in Figure 7e and represented in histogram in Figure 7d . On the other hand, KK1D04 showed tremendous recognition with mature monocytes (Figures 7b and c) implying that as cells differentiate into monocytes, the target protein is highly expressed. This may explain why KH1C12 signal intensity did not change but significantly increased for KK1B10 when the HL60 and NB4 cells were differentiated to monocytes.
Discussion
Using the strategy of the cell-based SELEX system, we report here the development of a molecular aptamer probe that can distinguish target HL60 cells from control NB4 cells, showing Molecular recognition of AML K Sefah et al the achieved specificity of selected aptamers. These two cell lines are closely related morphologically, 5 and that the leukemic cells of most patients with AML are generally homogenous with respect to the expression of myeloid cell surface antigens. 13 As such, it should have been very difficult to generate aptamers to distinguish between them. Nonetheless, we were able to accomplish this task by identifying aptamer KH1C12, which could selectively recognize the target HL60 cells, but not the negative control NB4 cells. Moreover, aptamer KH1C12 recognized HL60 with high affinity (4.5 nM), and its binding to target was not significantly influenced by increasing the temperature to 37 1C, a critical advantage in the development of probes for in vivo applications. We could not make comparison to any antibody in regard to this selective recognition potential as, to the best of our knowledge, there is no such antibody. At best, the antigens may be differentially expressed on the different myeloid cell lines. Apparently, we also identified aptamers that can recognize target as well as control cells. However, none of the aptamers selected against myeloid leukemia cell lines showed recognition to any of tested cell lines of T-or B-cell leukemias, or lymphomas. The counter selection strategy can help to select cell-specific aptamer probes, but it is not feasible to remove all the aptamer sequences that recognize both target and control cells. Other reported studies also showed similar findings and concluded that the counter selection strategy might not be completely effective. 3, 14 The preliminary observation that the selected aptamers can recognize real clinical patient samples is significant. This is an indication of the potential of these probes when they are well developed and optimized. Further testing of more clinical specimen will, however, be needed to fully establish the feasibility of further development of these aptamers for clinical use.
The HL60 and NB4 cell lines have played important roles as model cell systems in analyzing the various mechanisms underlying cellular differentiation events. For instance, microarray analysis of TPA-induced differentiation of HL-60 cells has resulted in the identification of a large number of genes that showed altered expression. A number of downstream targets were induced by TPA, and some of these are thought to be essential for the onset of differentiation. 15 Similarly, Yang et al. 16 reported that ATRA-induced differentiation of NB4 cells resulted in approximately 168 upregulated and more than 179 downregulated, genes. Many of the altered genes are thought to encode products that participate in signaling pathways, cell differentiation, programmed cell death, transcription regulation, and production of cytokines and chemokines. Therefore, knowing the molecular mechanisms associated with differentiation and maturation of hematopoietic cells may be useful for the manipulation of blood cell production. We, therefore, used these cell systems to assess the effect of cellular differentiation on the binding capacity of three aptamers selected by cell-based SELEX. To accomplish this, we compared the changes in fluorescence intensities of these aptamers as they interacted with undifferentiated and differentiated cells. Although the binding pattern of aptamer KH1C12 was not affected by cell differentiation, the fluorescent signals of both KK1B10 and KK1D04 aptamers to HL60 and NB4 cells were altered during chemically induced cell differentiation. Both aptamers showed decreased binding signals in ATRA-treated cells, but increased binding signals in sodium butyrate-treated cells, indicating their target proteins are differentially regulated in two different differentiation processes induced by two chemical products. There are several reports suggesting that both NB4 and HL60 cell lines can be induced to differentiate monocytic and granulocytic pathways depending on the chemical inducer, ATRA inducing granulocytic differentiation 17, 18 and sodium butyrate inducing monocytic/macrophage differentiation. 10, 11 Therefore, it is conceivable that the targets recognized by both KK1B10 and KK1D04 are associated with monocytic differentiation and they can potentially be useful probes for study of monocytic differentiation process. Our study suggests qualitative and quantitative differences in the protein targets of KK1B10 and KK1D04 occur during monocytic and granulocytic differentiation. Similarly, Mollinedo et al 10 observed that treatment of HL60 cells with sodium butyrate, induced monocytic differentiation, causing remarkable increase in AP-1 binding activity. Another monocytic differentiation agent 1-, 25-dihydroxyvitamin D3, induced a weak, but appreciable, increase in AP-1 activity. Furthermore, addition of sodium butyrate or 1-, 25-dihydroxyvitamin D3 to HL-60 cells induced the expression of c-fos, c-jun, jun B and jun D proto-oncogenes. In contrast, when HL-60 cells were treated with retinoic acid, a granulocytic differentiation inducer, no enhanced AP-1 binding activity was observed, and only a weak increase in jun D mRNA level was detected. The findings of our studies indicate that aptamer-based technology can also be used as a tool for comparative analysis between tumor cells and their differentiated forms, which could enable us to identify gene products that may have specific roles in cellular differentiation and tumor pathogenesis.
Malignancy, such as myeloid leukemias, is composed of tumor cells at different differentiation directions and at different differentiation stages. Leukemia cells are classified as myeloid leukemia as long as they show evidence of one of the following differentiation, erythroid, granulocytic, monocytic or megakaryocytic differentiation. Having molecular probes that can recognize a specific differentiation pathway would be very useful in leukemia studies, as well as in clinical leukemia diagnosis. Although this study only produced a few specific aptamers, it shows the capability of the cell-based aptamer selection strategy in identifying biomarkers 19, 20 for subclasses of AML and the potential for exploring new and useful disease surface markers. 
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